AUROPHARMA vs ERIS: Stock Comparison
AUROBINDO PHARMA is the larger company by market capitalisation. AUROBINDO PHARMA shows a lower P/E and lower leverage, while ERIS LIFESCIENCES shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AUROPHARMA leads 6; ERIS leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AUROPHARMA | ERIS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AUROPHARMA | ERIS |
|---|---|---|
| Live Price | ₹1,653.1 | ₹1,321.7 |
| Day Change | 0.97% | 1.4% |
| Volume | 5.74 L | 69,111 |
| 52-Week High | ₹1,717 | ₹1,797.6 |
| 52-Week Low | ₹1,033.1 | ₹1,200 |
| Distance from 52W High | -3.72% | -26.47% |
Valuation
| Metric | AUROPHARMA | ERIS |
|---|---|---|
| Market Cap | ₹95,127 Cr | ₹18,299 Cr |
| P/E Ratio | 25.84x | 28.56x |
| P/B Ratio | 2.54x | 4.74x |
| EPS | ₹17.95 | ₹3.49 |
| Book Value | ₹658.4 | ₹281.12 |
| Dividend Yield | 0% | 0.55% |
Growth
| Metric | AUROPHARMA | ERIS |
|---|---|---|
| Revenue Growth (TTM YoY) | 5.6% | 7.1% |
| EPS Growth (TTM YoY) | 1.9% | 200% |
| Qtr Sales Growth | 226.86% | -49.16% |
| Qtr Profit Growth | 39.99% | -66.3% |
Profitability & Leverage
| Metric | AUROPHARMA | ERIS |
|---|---|---|
| ROE | 9.25% | 16.62% |
| ROCE | 10.23% | 13.51% |
| Net Margin | 10.62% | 19.89% |
| Operating Margin | 16.33% | 26.56% |
| Debt to Equity | 0.2x | 0.59x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AUROPHARMA | ERIS |
|---|---|---|
| Promoter Holding | 48.81%▲ 0.06 pp | 54.14%▲ 0.22 pp |
| FII Holding | 16.38%▲ 1.14 pp | 5.75%▼ 0.64 pp |
| DII Holding | 25.1%▼ 0.77 pp | 20.72%▲ 0.37 pp |
| Public Holding | 6.64%▼ 0.44 pp | 19.4%▲ 0.07 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AUROBINDO PHARMA and ERIS LIFESCIENCES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.